(NASDAQ: NEO) Neogenomics's forecast annual revenue growth rate of 10.93% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.5%.
Neogenomics's revenue in 2025 is $672,361,000.On average, 7 Wall Street analysts forecast NEO's revenue for 2025 to be $95,002,024,726, with the lowest NEO revenue forecast at $94,603,329,155, and the highest NEO revenue forecast at $95,298,279,472. On average, 7 Wall Street analysts forecast NEO's revenue for 2026 to be $105,780,189,352, with the lowest NEO revenue forecast at $104,139,591,828, and the highest NEO revenue forecast at $106,757,238,019.
In 2027, NEO is forecast to generate $119,086,557,490 in revenue, with the lowest revenue forecast at $117,768,339,695 and the highest revenue forecast at $120,024,354,333.